3920-37-4

Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIMETHYL-4-NITRO-2 H-PYRAZOLE-3-CARBOXYLIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2,5-DIMETHYL-4-NITRO-2 H-PYRAZOLE-3-CARBOXYLIC ACID is utilized as a precursor in the production of agrochemicals, which can be employed for pest control and crop protection, enhancing agricultural productivity.
Used in Organic Chemistry:
2,5-DIMETHYL-4-NITRO-2 H-PYRAZOLE-3-CARBOXYLIC ACID is used as a building block in the preparation of various organic compounds, facilitating the creation of a wide range of chemical entities for research and industrial applications.

Upstream product

• 5744-56-9 1,3-dimethylpyrazol-5-carboxylic acid 
• 615-79-2 ethyl 2,4-diketopentanoate 
• 5744-40-1 ethyl 1,3-dimethylpyrazole-5-carboxylate 
• 67208-10-0 4-iodo-2,5-dimethyl-2H-pyrazole-3-carboxylic acid 
• 78208-69-2 methyl 1,3-dimethyl-4-nitro-1H-pyrazole-5-carboxylate 

Downstream Products

• 37141-71-2 1,3-dimethyl-4-nitro-1H-pyrazole-5-carbonyl chloride 
• 1285500-15-3 (S)-1-ethyl-3-(4-(7-(3-ethylmorpholino)-1,3-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)urea 
• 1285500-07-3 (S)-4-(5-chloro-1,3-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)-3-ethylmorpholine 
• 928767-13-9 5,7-dichloro-1,3-dimethyl-1H-pyrazolo[4,3-d]pyrimidine 
• 109421-37-6 1,3-dimethyl-1H-pyrazolo[4,3-d]pyrimidine-5,7(4H,6H)-dione 
• 104393-45-5 4-(1,3-dimethyl-7-oxopyrazolo<4,3-d>pyrimidin-5-yl)-N-<2-(dimethylamino)ethyl>benzenesulfonamide 
• 104393-36-4 5-(2-Chloro-4-nitro-phenyl)-1,3-dimethyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one 
• 104393-34-2 4-(1,3-dimethyl-7-oxopyrazolo<4,3-d>pyrimidin-5-yl)benzenesulfonic acid 
• 104393-52-4 4-(3,5-Dimethoxy-benzoylamino)-2,5-dimethyl-2H-pyrazole-3-carboxylic acid amide 
• 104393-35-3 1,3-Dimethyl-5-(4-trifluoromethyl-phenyl)-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one 
• 104393-33-1 5-(2,4-Dimethoxy-phenyl)-1,3-dimethyl-1,6-dihydro-pyrazolo[4,3-d]pyrimidin-7-one 
• 104393-51-3 4-(3,4-Dichloro-benzoylamino)-2,5-dimethyl-2H-pyrazole-3-carboxylic acid amide 
• 104393-50-2 4-(2-Methoxy-benzoylamino)-2,5-dimethyl-2H-pyrazole-3-carboxylic acid amide 

Relevant academic research and scientific papers

SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS

The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by NADPH oxidase. (Formula I)

A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors

A series of N-7-methyl-imidazolopyrimidine inhibitors of the mTOR kinase have been designed and prepared, based on the hypothesis that the N-7-methyl substituent on imidazolopyrimidine would impart selectivity for mTOR over the related PI3Kα and δ kinases. The corresponding N-Me substituted pyrrolo[3,2-d]pyrimidines and pyrazolo[4,3-d]pyrimidines also show potent mTOR inhibition with selectivity toward both PI3α and δ kinases. The most potent compound synthesized is pyrazolo[4,3-d]pyrimidine 21c. Compound 21c shows a Ki of 2 nM against mTOR inhibition, remarkable selectivity (>2900×) over PI3 kinases, and excellent potency in cell-based assays.

N-7 SUBSTITUTED PURINE AND PYRAZOLOPYRIMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE

The present invention relates to compounds of Formula I: wherein R1, R2, R3, A1, A2, A3, A4, Y1 and Y2 and D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.

Nitrodeiodination of 4-iodo-1-methylpyrazoles

4-Iodo-1-methylpyrazoles react with a nitrating mixture at 55°C to give the corresponding 4-nitro-1-methylpyrazoles. The qualitative dependence of the nitrodeiodination rate on the structure of the heterocycles and the reaction conditions was considered.

Synthesis and antitumor activity of a new class of pyrazolo[4,3- e]pyrrolo[1,2-a][1,4]diazepinone analogues of pyrrolo[1,4][2,1- c]benzodiazepines

A new class of pyrrolo[1,4]benzodiazepine (PBD) analogues featuring a pyrazolo[4,3-e]pyrrolo[1,2-a][1,4]diazepinone ring system has been designed and synthesized. These compounds, 2a-o, are characterized by the substitution of the aromatic A ring, characteristic of the PBDs, with a disubstituted pyrazole ring bearing alkyl and benzyl substituents at N6 or N7 and alkyl or carbomethoxy substituents at C8. Biological evaluation revealed an appreciable in vitro cytotoxic activity for compounds 2a,b,f-i.

Synthesis and Structure-Activity Relationships of Pyrazolopyrimidin-7-ones as Adenosine Receptor Antagonists

A series of 21 1,3-dialkylpyrazolopyrimidin-7-ones substituted in the 5-position with various phenyl substituents has been synthesized and found to have affinity for the adenosine A1 receptor.The potency pattern due to substituents of the phenyl ring was found to parallel that found in a previously reported 1,3-dialkyl-8-phenylxanthine series.A quantitative structure-activity relationship was developed between these two series that correctly predicted the potencies of six additional 5-substituted pyrazolopyrimidines that were synthesized during the course of the analysis.With use of the correlation as a guide, one additional 5-phenylpyrazolopyrimidine containing a 4amino>sulfonyl substituent to improve aqueous solubility was prepared.On the basis of the high correlation between adenosine binding affinities of analogously substituted xanthines and pyrazolopyrimidines and the close superposition of the heterocyclic rings and substituents that is apparent from molecular models of these two series (Figure 2), it is hypothesized they fit the receptor in an analogous fashion.

PYRAZOLO[4,3-D]PYRIMIDINE-5,7-(4H,6H)DIONE OR -5-THIONE-7-ONE ANALOGS

Various novel analogs of pyrazolo 4,3d!pyrimidine-5,7-(4H,6H) diones and also 5-thione-7-ones, novel methods of synthesis therefor, compositions and uses are the present invention. For example, the novel 5, 7-diones and 5-thione-7-ones are useful for stimulating the central nervous system reversing bronchoconstriction, and as cardiac stimulants cardiotonic agents.

5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use

The present invention relates to novel 5-substituted pyrazolo[4,3-d]pyrimidine-7-one compounds, and compositions, methods of use and processes to make therefor. The novel compounds are useful in the treatment of cardiovascular disorders, such as heart failure or cardiac insufficiency. The novel compounds bind adenosine receptors and selectively inhibit phosphodiesterase.

Pyrazolodiazepines. 1,3 (and 2,3) dialkyl 4,6 dihydro 8 arylpyrazolo[4,3 e][1,4] diazepin 5 ones as antianxiety agents

A series of 1, 3 (and 2, 3) dialkyl 4, 6 dihydro 8 arylpyrazolo [4, 3 e][1, 4] diazepin 5 ones was synthesized and evaluated for psychotropic activity. Intermediates are new dialkylnitropyrazolyl aryl ketones prepared from dialkylnitropyrazolecarboxylic acids. Many of these pyrazolodiazepines exhibit high CNS activity in animals. One compound, 1 ethyl 4, 6 dihydro 3 methyl 8 phenylpyrazolo [4, 3 e] [1, 4] diazepin 5 (1H) one is about as potent as diazepam as an antianxiety agent with less sedative properties and is being studied in the clinic.